BioCentury
ARTICLE | Company News

Medifocus, Ideal Concept Group Ltd. sales and marketing update

November 25, 2013 8:00 AM UTC

Medifocus and Ideal Concept will form a JV to commercialize Medifocus' Prolieve Thermodilatation System in China and other Asian countries to treat benign prostatic hyperplasia (BPH). The JV will seek regulatory approval from China's Food and Drug Administration (CFDA), seek distributers and identify and select GMP compliant manufacturers for Prolieve. Prolieve is approved in the U.S. to treat BPH. Medifocus gained the device that uses intra-cavitary catheters to deliver a combination of microwave heating and balloon dilatation of the prostatic urethra from Boston Scientific Corp. (NYSE:BSX, Natick, Mass.) in 2012. Medifocus will own 40% of the JV and Ideal Concept will own 60% (see BioCentury, Oct. 8, 2012). ...